The time of Covid-19 crisis has very clearly shown that there are problems with supplies of pharmaceutical products. For example, there is simply no available...
Today, on 30 May, the JSC Grindeks submitted the non-audited consolidated financial statements of the first quarter of 2019 to Nasdaq Riga. Non-audited financial results...
Today, on 30 April, the JSC Grindeks submitted the audited consolidated financial statements and Non-financial statement for 2019 to Nasdaq Riga. Audited financial results indicate...
Joint stock company Grindeks in collaboration with Latvian Psychiatric association, has developed and launched the mobile application* “Mood tracker Grindeks”, which helps doctors to supervise...
JSC Grindeks announces that it has completed the Phase 1 clinical study of its new investigational medicinal product metyl-GBB. This new investigational medicinal product is...
Today, on 28 February, the JSC Grindeks submitted the non-audited consolidated financial statements of 2019 to Nasdaq Riga. Non-audited financial results indicate that the Group’s...
JSC Grindeks announces that the company’s Supervisory Council has approved Juris Hmelnickis as the Chairman of the Board. Kirovs Lipmans, Chairman of the Council of...
